Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Admiraal, Rick  [Clear All Filters]
2023
Duncan N, Moreno-Martinez M-E, Pires V, Domingos V, Bonnin A, Nezvalova-Henriksen K, Admiraal R, Bauters T, Langebrake C. Role and competencies of the EBMT clinical pharmacists and clinical pharmacologists: a pan-European survey. Bone Marrow Transplant. 2023.
2022
Admiraal R, Nierkens S, Bierings MB, Bredius RGM, van Vliet I, Jiang Y, Lopez-Yurda M, A Versluijs B, C Zwaan M, Lindemans CA, et al. Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial. Lancet Haematol. 2022;9(2):e111-e120.
2020
Admiraal R, Boelens JJ. Anti-thymocyte globulin for GVHD: one dose does not fit all. Lancet Haematol. 2020;7(7):e505.
2015
Admiraal R, van Kesteren C, van der Zijde CMJol-, Lankester AC, Bierings MB, Egberts TCG, van Tol MJD, Knibbe CAJ, Bredius RGM, Boelens JJ. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematol. 2015;2(5):e194-203.
2014
Willemsen L, van der Zijde CMJol-, Admiraal R, Putter H, Jansen-Hoogendijk AM, Dam MMOstaijen, Wijnen JT, van Kesteren C, Waaijer JLM, Lankester AC, et al. Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab. Biol Blood Marrow Transplant. 2014.